OSTO:ERMA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
OSTO:ERMA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Enorama Pharma AB's enterprise value is kr178.18 Mil. Enorama Pharma AB's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 was kr-29.00 Mil. Therefore, Enorama Pharma AB's EV-to-EBITDA for today is -6.14.
The historical rank and industry rank for Enorama Pharma AB's EV-to-EBITDA or its related term are showing as below:
During the past 10 years, the highest EV-to-EBITDA of Enorama Pharma AB was -0.78. The lowest was -101.41. And the median was -7.23.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-12-14), Enorama Pharma AB's stock price is kr3.10. Enorama Pharma AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was kr-0.671. Therefore, Enorama Pharma AB's PE Ratio (TTM) for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
The historical data trend for Enorama Pharma AB's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enorama Pharma AB Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
EV-to-EBITDA | Get a 7-Day Free Trial | -9.22 | -8.66 | -6.36 | -0.86 | -3.02 |
Enorama Pharma AB Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
EV-to-EBITDA | Get a 7-Day Free Trial | -3.58 | -3.02 | -3.29 | -4.76 | -9.06 |
For the Drug Manufacturers - Specialty & Generic subindustry, Enorama Pharma AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Enorama Pharma AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Enorama Pharma AB's EV-to-EBITDA falls into.
Enorama Pharma AB's EV-to-EBITDA for today is calculated as:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA (TTM) |
= | 178.183 | / | -28.997 | |
= | -6.14 |
Enorama Pharma AB's current Enterprise Value is kr178.18 Mil.
Enorama Pharma AB's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-29.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enorama Pharma AB (OSTO:ERMA) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Enorama Pharma AB's PE Ratio (TTM) for today is calculated as:
PE Ratio (TTM) | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 3.10 | / | -0.671 | |
= | At Loss |
Enorama Pharma AB's share price for today is kr3.10.
Enorama Pharma AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.671.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Please read Which price ratio outperforms the enterprise multiple?
Thank you for viewing the detailed overview of Enorama Pharma AB's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
No Headlines
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.